Cargando…

HAND-FOOT SYNDROME DUE TO CAPECITABINE

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Surjushe, Amar, Vasani, Resham, Medhekar, Sudhir, Thakre, Minal, Saple, D G
Formato:	Texto
Lenguaje:	English
Publicado:	Medknow Publications 2009
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2810708/ https://www.ncbi.nlm.nih.gov/pubmed/20161873 http://dx.doi.org/10.4103/0019-5154.55651

Ejemplares similares

HAND-FOOT SYNDROME DUE TO CAPECITABINE
por: Surjushe, Amar, et al.
Publicado: (2008)

ALOE VERA: A SHORT REVIEW
por: Surjushe, Amar, et al.
Publicado: (2008)

Generalised Lichenoid Drug Eruption Accompanied by Hand-foot Syndrome Due to Capecitabine
por: Tamer, Funda, et al.
Publicado: (2018)

Urticaria pigmentosa
por: Vasani, Resham J., et al.
Publicado: (2015)

Leukocytoclastic Vasculitis: A Window to Systemic Churg Strauss Syndrome
por: Medhekar, Sudhir V, et al.
Publicado: (2012)

Development of Secondary Prurigo Nodularis in Steroid Modified Tinea Corporis- Documenting a Curious Phenomenon
por: Verma, Shyam Bhanushankar, et al.
Publicado: (2022)

Bowen's disease on the dorsum of hand
por: Vasani, Resham J.
Publicado: (2015)

Scleroderma in a Patient on Capecitabine: Is this a Variant of Hand-Foot Syndrome?
por: Saif, Muhammad W, et al.
Publicado: (2016)

Hyperpigmentation with Capecitabine: Part of Hand-Foot Syndrome or a Separate Entity?
por: Caprez, Jennifer, et al.
Publicado: (2018)

Nasal Involvement in Hand and Foot Syndrome
por: Mishra, Anil, et al.
Publicado: (2013)

Hand-Foot Syndrome Presentation Post-Capecitabine Treatment in a Black Patient
por: Whorton, Allison E, et al.
Publicado: (2022)

Lymphoma in HIV patients: Varied presentations
por: Saple, Dattatray G., et al.
Publicado: (2010)

Hand-foot syndrome caused by capecitabine: incidence, risk factors and the role of dermatological evaluation
por: de Queiroz, Marina Vieira Rodrigues, et al.
Publicado: (2022)

Gemcitabine and Docetaxel Combination Chemotherapy Induced Dermatomyositis Associated with Hand-Foot Syndrome
por: Kawada, Mayuko, et al.
Publicado: (2021)

Stevens-Johnson syndrome and concurrent hand foot syndrome during treatment with capecitabine: A case report
por: Ahn, Ha Rim, et al.
Publicado: (2021)

Hand-Foot Syndrome with Scleroderma-like Change Induced by the Oral Capecitabine: A Case Report
por: Lee, Sehe-Dong, et al.
Publicado: (2007)

Henna Application in the Prevention of Capecitabine-Induced Hand-Foot Syndrome in Breast and Colorectal Cancer Patients
por: Kayikci, Emel Emine, et al.
Publicado: (2020)

Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer
por: Dong, Si-Qi, et al.
Publicado: (2021)

Capecitabine-induced oral mucosal hyperpigmentation associated with hand-foot syndrome – A literature review()
por: Nascimento, Anna Danielly Almeida do, et al.
Publicado: (2023)

Compliance and Effective Management of the Hand-Foot Syndrome in Colon Cancer Patients Receiving Capecitabine as Adjuvant Chemotherapy
por: Son, Hyun-Sook, et al.
Publicado: (2009)

An unusual case of capecitabine hyperpigmentation: Is hyperpigmentation a part of hand-foot syndrome or a separate entity?
por: Vasudevan, Biju
Publicado: (2010)

Treatment of capecitabine-induced hand-foot syndrome using a topical retinoid: A case report
por: INOKUCHI, MASAFUMI, et al.
Publicado: (2014)

Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer
por: Lin, Shaoyan, et al.
Publicado: (2019)

Use of omeprazole, the proton pump inhibitor, as a potential therapy for the capecitabine-induced hand-foot syndrome
por: Hiromoto, Shiori, et al.
Publicado: (2021)

Relapse of Hand Foot and Mouth Disease: Are We at More Risk?
por: Sarma, Nilendu
Publicado: (2013)

Evaluation of patient-reported severity of hand–foot syndrome under capecitabine using a Markov modeling approach
por: Schmulenson, Eduard, et al.
Publicado: (2020)

Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand‐foot syndrome
por: Watts, Katie, et al.
Publicado: (2022)

The resurfacing of hand, foot, and mouth disease: Are we on the verge of another epidemic?
por: Farahat, Ramadan Abdelmoez, et al.
Publicado: (2022)

Pilonidal Disease on the Dorsum of the Hand and Sole of the Foot Diagnosed by Superficial Echography
por: Shiratori, Takahiro, et al.
Publicado: (2022)

Nasolacrimal Duct Stenosis after Oral Capecitabine Administration
por: Jang, Yeonji, et al.
Publicado: (2019)

Successful Management of Dowling-Degos Disease with Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser
por: Tambe, Swagata Arvind, et al.
Publicado: (2017)

Capecitabine-associated hand–foot–skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer
por: Hofheinz, R-D, et al.
Publicado: (2012)

Outbreak of Hand, Foot, and Mouth Disease in Udaipur
por: Agarwal, Nidheesh, et al.
Publicado: (2015)

Squamous Cell Carcinoma of the Nail Bed: The Great Mimicker
por: Tambe, Swagata Arvind, et al.
Publicado: (2017)

Concomitant Onychomadesis and Skin Rash in a 3-Year-Old Child Affected by Hand, Foot, and Mouth Disease
por: Sechi, Andrea, et al.
Publicado: (2021)

Response to oral acitretin in lichen amyloidosis
por: Vasani, Resham J.
Publicado: (2014)

Facial Angiofibromas of Tuberous Sclerosis Treated with Topical Sirolimus in an Indian Patient
por: Vasani, Resham J
Publicado: (2015)

Idiopathic Eruptive Macular Pigmentation - Uncommon Presentation of an Uncommon Condition
por: Vasani, Resham Jayvant
Publicado: (2018)

Predictive role of hand–foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer
por: Zielinski, Christoph, et al.
Publicado: (2016)

Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study)
por: Santhosh, Akhil, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fibi3q2umi8t748o2p0afm7jme